1 August 2018 in Journal of Oral Implantology
The success of osseointegration is influenced by several factors that affect bone metabolism and by certain systemic medications. Selective serotonin reuptake inhibitors (SSRIs) have been previously suggested to be among these medications. This study aims to investigate the association between systemic intake of SSRIs and failure of osseointegration in patients rehabilitated with dental implants. A retrospective cohort study was conducted, including a total of 2055 osseointegrated dental implants in 631 patients (109 implants in 36 SSRI \users and 1946 in 595 nonusers). Predictor and outcome variables were SSRI intake and osseointegration failure, respectively. The data were analyzed with Mann–Whitney test or Fisher exact test accordingly. Both patient-level and implant-level models were implemented to evaluate the effect of SSRI exposure on the success of osseointegration of dental implants. Median duration of follow-up was 21.5 months (range = 4–56 months) for SSRI users and 23 months (range –60 months) for nonusers (P = .158). Two of 36 SSRI users had 1 failed implant each; thus, the failure rate was 5.6%. Eleven nonusers also had 1 failed implant each; thus, the failure rate was 1.85%. The difference between the 2 groups failed to reach statistical significance at patient and implant levels (P = .166, P = .149, respectively). The odds of implant failure were 3.123 times greater for SSRI users compared with nonusers. Patients using SSRIs were found to be 3.005 times more likely to experience early implant failure than nonusers. The results of this study suggest that SSRIs may lead to increase in the rate of osseointegration failure, although not reaching statistical significance.
1 January 2019 in Journal of the Korean Association of Oral and Maxillofacial Surgeons
Altay MA, et al. J Korean Assoc Oral Maxillofac Surg. 2019 Jun;45(3):135-140. https://doi.org/10.5125/jkaoms.2019.45.3.135
1 January 2018 in The International Journal of Oral and Maxillofacial Implants
Mehmet Ali Altay, DDS, PhD/Sinan Tozoğlu, DDS, PhD/Nelli Yıldırımyan, DDS/Mehmet Mustafa Özarslan, DDS, PhD: Purpose: The aim of this pilot study was to evaluate clinical outcomes of implant treatment in periodontally compromised patients. Materials and Methods: Partially edentulous patients who were diagnosed and treated for chronic periodontitis and later rehabilitated with implant-supported single crowns or fixed partial dentures were enrolled in this study. At the final follow-up, data on probing pocket depth and bleeding on probing were collected, and changes in peri-implant bone levels were assessed on periapical radiographs. Accordingly, patients were categorized into peri-implant disease–free (PID-free), peri-implant mucositis (PIM), or peri-implantitis (PI) groups. Additionally, information on the history of systemic diseases was obtained and correlated with the findings. Results: Seven females and six males with a mean age of 55.2 (standard deviation [SD] ± 8.38) years were included in this study. Fifty-five implants were placed in 13 partially edentulous patients with a history of chronic periodontitis. The mean follow-up in the study was 35.1 (SD ± 2.40) months. No implants were lost in the 13 patients, for a cumulative survival of 100%. PI was confirmed in 3 patients and PIM in 8 patients, while 2 patients were found to be PID-free. Diabetes and hypertension were found to be the predominant systemic factors among patients affected by peri-implant diseases. Conclusion: Patients with a history of periodontitis are at considerable risk of being affected by peri-implant mucositis, if not by peri-implantitis.
9 October 2018 in Cranio®
Objectives: This study aimed to evaluate and report the outcomes associated with the management of patients who were treated surgically for medication-related osteonecrosis of the jaw (MRONJ).Methods: Demographic and medical profiles of patients with a diagnosis of MRONJ were created. The type of surgical treatment, complications, and treatment outcomes were identified.Results: Twenty-one patients with an average age of 68.42 years (range 40–90 years) were included. Nineteen patients had only mandible involvement, one patient had only maxilla involvement, and one patient had both mandible and maxilla involvement. Thirteen patients underwent marginal resections. Eight patients underwent segmental resection of the mandible with immediate reconstruction. Nineteen patients healed without any complications. Two patients who had undergone segmental resection of the mandible experienced postoperative complications and needed a second surgery to achieve primary closure.Discussion: Advanced MRONJ can effectively be treated with resective surgery in combination with medical treatment.
1 February 2018 in Implant Dentistry
Purpose: This report describes a novel technique that allows for 3-dimensional augmentation of localized bone defects of the posterior maxilla and simultaneous implant placement by means of using the maxillary tuberosity as a block graft. Materials and Methods: The residual bone in maxillary tuberosity is harvested as a whole. The recipient site and the bone graft are prepared with compatible implant drills. The bone graft is flipped to fit the defect and fixated in place using the dental implant, which anchors both the graft and the subantral bone. Results: The defect of the posterior maxilla is reconstructed with autogenous bone harvested from maxillary tuberosity, and simultaneous implant placement is achieved. Conclusion: The proposed technique enables the clinician to reconstruct alveolar defects of the posterior maxilla without the need for an additional donor site and simultaneously place dental implants.
1 May 2018 in İstanbul Tıp Fakültesi Dergisi
SNSumit K. Nijhawan Nijhawan
Sumit K. Nijhawan Nijhawan
+1
İstanbul Üniversitesi | Tarihten Geleceğe Bilim Köprüsü - 1453